Tardive dyskinesia is a neurological movement disorder characterized by involuntary and repetitive movements. It most commonly develops after exposure to dopamine receptor blocking medicines, particularly antipsychotic medications. Symptoms may involve the tongue, lips, jaw, face, limbs, or trunk. The condition can develop after months or years of medication exposure, although the timing varies between individuals.
The primary cause of tardive dyskinesia is prolonged exposure to medicines that block dopamine receptors in the brain. These medicines can alter dopamine signaling in areas involved in movement control. Antipsychotics are the most common medications associated with TD, while certain medicines used for nausea and gastrointestinal problems can also contribute to the condition.
Several medication related factors can influence the likelihood of developing TD:
Second generation antipsychotics generally have a lower risk than many first generation medications, but they can still cause tardive dyskinesia. Therefore, the possibility of TD is not completely eliminated by using newer medications.
Not everyone who takes a dopamine receptor blocking medication develops tardive dyskinesia. Individual characteristics and existing health conditions can affect susceptibility. Older age is one of the strongest established risk factors, and TD is also more frequently reported among women. Other factors include certain psychiatric conditions, diabetes, previous movement disorders, and greater cumulative exposure to medications associated with TD.
Important risk factors may include:
Having one or more risk factors does not mean that a person will definitely develop tardive dyskinesia. Risk factors indicate increased susceptibility rather than certainty. Genetic factors have also been studied, but current evidence is not strong enough to routinely predict TD through genetic testing.
Recognizing the possible causes and risk factors of tardive dyskinesia can help support appropriate awareness and medical monitoring. People taking medications associated with TD should discuss unusual or persistent involuntary movements with a healthcare professional. Medication should not be stopped or changed without professional guidance because sudden changes may create other health risks.